Thermo Fisher Surges 9.42% on $3.17B Volume Ranks 24th in U.S. Trading Amid Diagnostic Expansion

Thermo Fisher Scientific (TMO) surged 9.42% on October 1, 2025, with a trading volume of $3.17 billion—marking a 52.76% increase from the previous day’s activity. The biotech giant ranked 24th in overall trading volume across U.S. markets, reflecting heightened investor interest amid strategic developments in its diagnostic and life sciences divisions.

Analysts attributed the rally to recent operational updates, including expanded partnerships in genomic sequencing and enhanced R&D pipeline visibility. While no immediate earnings reports or acquisitions were disclosed, the stock’s performance aligned with broader sector momentum driven by renewed demand for advanced diagnostic tools.

To run this back-test accurately, I need to pin down a few implementation details: Universe selection (all U.S. listed common stocks or a narrower index), daily ranking mechanics (e.g., equal-weight rebalancing thresholds), transaction cost assumptions, and risk-control overlays. Once parameters are defined, the data-retrieval plan can be finalized for execution.